<DOC>
	<DOCNO>NCT02202356</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( PK ) anti-viral effect single multiple dos ALS-008176 infant hospitalize respiratory syncytial virus ( RSV )</brief_summary>
	<brief_title>A Study ALS-008176 Infants Hospitalized With RSV</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Male female infant ≥1.0 ≤12.0 month age ( inclusive ) , define time hospital admission , &lt; 28 day age ( neonate cohort ) . Note : subject , include neonate , must discharge hospital birth admit due RSV relate illness Prematurity Receiving invasive endotracheal mechanical ventilation Poorly function gastrointestinal tract Anticipated discharge hospital &lt; 24 hour time randomization Prior exposure palivizumab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>